JNJ · News · 20260909N

Guidance and Outlook

JOHNSON & JOHNSON · 2026-09-09 · Importance 41 · Surprise 32

Johnson & Johnson’s MedTech chairman said the company remains confident in delivering growth at the high end of its previously stated 5% to 7% operational market-growth range. The outlook applies to the 2022–2027 period. Management attributed the expected performance to a portfolio shift toward cardiovascular products, operating-model changes, and continued investment in differentiated technologies.

Key facts

• Johnson & Johnson remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period. source
• Johnson & Johnson is implementing operating-model changes. source